Lineage, Inc. Common Stock (LINE)vsRe Max Holding (RMAX)
LINE
Lineage, Inc. Common Stock
$37.75
+0.96%
REAL ESTATE · Cap: $9.50B
RMAX
Re Max Holding
$12.36
0.00%
REAL ESTATE · Cap: $681.16M
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 1797% more annual revenue ($5.37B vs $283.12M). RMAX leads profitability with a -3.0% profit margin vs -3.1%. RMAX earns a higher WallStSmart Score of 40/100 (D).
LINE
Avoid35
out of 100
Grade: F
RMAX
Hold40
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
0.0% earnings growth
Operating margin of 3.7%
Elevated debt levels
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
ROE of -1.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : RMAX
The strongest argument for RMAX centers on Price/Book.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : RMAX
The primary concerns for RMAX are Market Cap, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
RMAX carries more volatility with a beta of 1.84 — expect wider price swings.
LINE is growing revenue faster at 0.8% — sustainability is the question.
LINE generates stronger free cash flow (186M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMAX scores higher overall (40/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →Re Max Holding
REAL ESTATE · REAL ESTATE SERVICES · USA
RE / MAX Holdings, Inc. is a franchisor of real estate and mortgage brokerage services in the United States, Canada, and internationally. The company is headquartered in Denver, Colorado.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?